Global Vaccines Market Size, Share, Growth & Trends Report Segmented by Vaccine Type (Recombinant, Conjugate, Inactivated, mRNA), Route of Administration (Oral, Parenteral, Nasal), Disease Type (Viral, Bacterial, Cancer), Age and Distribution Channel, & Regional Forecast to 2031

The Vaccines Market encompasses the research, development, production, and distribution of vaccines, which are biological preparations that stimulate an individual’s immune system to provide immunity against specific diseases. These products include preventive vaccines administered across pediatric, adult, and geriatric populations, as well as emerging therapeutic vaccines targeting chronic and infectious diseases. These vaccines are crucial in preventing infectious diseases and reducing mortality rates worldwide. These vaccines are derived from attenuated or inactivated organisms, recombinant proteins, or newer platforms such as mRNA and viral vectors. The market includes vaccines targeting viral, bacterial, and parasitic infections, administered through government immunization programs, private healthcare providers, and non-profit organizations.

Rising global demand: Addressing the surge in infectious diseases

The increasing global incidence of infectious diseases remains a central factor supporting expansion in the vaccines market. Rising concerns around conditions such as COVID-19, seasonal influenza, hepatitis, and human papillomavirus (HPV) have reinforced the importance of accessible and effective immunization. Health authorities and governments continue to prioritize vaccination programs to limit disease spread, reduce the economic burden of treatment, and improve population-level health outcomes. In addition to individual protection, vaccines play a crucial role in establishing broader community immunity, encouraging wider uptake across different demographic groups. The surge in infectious disease awareness has further accelerated vaccination acceptance, particularly with the growing need for booster doses and targeted immunization strategies for adults and international travellers.

Beyond disease prevalence, the expansion of national immunization programs in emerging economies has strengthened baseline demand, with governments allocating higher healthcare spending toward preventive care and incorporating newer vaccines into routine schedules. Population growth and urbanization patterns are further contributing to the need for structured immunization strategies, particularly in densely populated regions. This trend is especially prominent in rapidly developing regions such as Asia-Pacific, where improving healthcare access and awareness are supporting higher vaccination coverage across diverse population groups. The awareness generated by recurring outbreaks and pandemic events continues to reinforce vaccination as a key component of healthcare systems globally. Additionally, ongoing efforts to control vaccine-preventable diseases are increasingly aligned with global initiatives to address antimicrobial resistance, reinforcing the long-term importance of immunization in reducing dependence on antibiotic treatments and supporting sustained market growth.

To learn more about this report, download the PDF brochure

Transformative innovation: Advancements in mRNA vaccine technology

Advancements in mRNA vaccine technology are reshaping the vaccine landscape by enabling faster and more adaptable development processes, moving from a reactive, long-cycle process to a highly adaptive, rapid-response model. This approach uses genetic instructions to stimulate internal immune responses, allowing vaccines to be designed and produced with greater speed compared to traditional methods, as demonstrated by the rapid development of COVID-19 vaccines, which reached large-scale deployment within an unprecedented timeframe. This success has acted as a catalyst, shifting research focus toward long-term applications in infectious diseases, oncology, and personalized therapeutics. 

Beyond COVID-19, progress in platform technologies, including mRNA, DNA-based systems, and viral vectors, has introduced greater flexibility in antigen design. Modern manufacturing, using continuous flow technologies and AI-integrated design, now offers increased scalability and significantly reduced costs. These innovations are supporting the development of combination vaccines and expanding research into applications beyond infectious diseases, including oncology and other therapeutic areas. As research pipelines evolve, these technologies are expected to support more targeted and efficient vaccine solutions, contributing to ongoing shifts in how vaccines are developed and utilized.

To learn more about this report, download the PDF brochure

Vaccine Type Segment Outlook

The global vaccines market is segmented by vaccine type into subunit vaccines (conjugate/recombinant), mRNA, viral vector, inactivated, and live attenuated vaccines. The conjugate/recombinant vaccine leads the global market due to its strong, long-lasting immunity, especially for pediatric and immunocompromised populations. Further, mRNA vaccines are being recognized for their rapid antigen development; this segment is expected to show the fastest growth rate, driven by COVID-19 and by the potential for cancer/infectious disease applications. Inactivated vaccines represent a mature segment capturing a significant share, commonly used for diseases such as polio, rabies, and hepatitis A, and often utilized in national immunization programs due to high stability. Live attenuated vaccines are used for long-term immunity against diseases like measles, mumps, and rubella. Lastly, Viral vector vaccines, which gained prominence during the COVID-19 pandemic, remain a key platform utilizing vectors to deliver genetic material.

Regional Outlook: North America to maintains its vaccine market leadership through advanced R&D and robust healthcare infrastructure

North America holds a significant share of the vaccine market, supported by advanced healthcare infrastructure, established immunization programs, and the presence of key market players. Further, rising investments in R&D and the rapid adoption of new vaccine technologies contribute to steady growth in the region. Europe follows closely, with a strong focus on public healthcare systems and coordinated vaccination policies. Moreover, increasing focus on adult immunization and booster programs is further increasing the vaccine demand across the region. The Asia-Pacific region is expected to witness the fastest growth rate in the global vaccine market. The region's growth is driven by rising incidence of infectious diseases, large population bases, and improving healthcare access. Furthermore, advancements in vaccine technology (like mRNA) and government-led immunization initiatives are significantly boosting the region’s growth.

Competitive Landscape Analysis

The global vaccines market is marked by the presence of established and emerging market players such as Merck & Co. Inc. (US); Pfizer Inc. (US); Moderna Inc. (US); CLS Seqirus (AU); Sanofi SA (France); GSK Plc. (UK); Sinovac Biotech Ltd (China); BioNTech SE (Germany); AstraZeneca (UK); Serum Institute of India Pvt. Ltd. (India); and Emergent BioSolutions Inc. (US), among others.

Get a sample report for competitive landscape analysis

Growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting various growth strategies such as new product launches and approvals; acquisitions; expansions; and strategic partnerships, agreements, and collaborations, to garner market share. For instance,

• In June 2025, US-based CDMO ProBio opened its flagship 128,000 sq ft GMP facility in Hopewell, New Jersey, to expand plasmid DNA and viral vector manufacturing capacity, supporting clinical development and large-scale production of gene and cell therapies
• In November 2024, SyVento BioTech launched a new mRNA manufacturing facility in Poland, equipped with Cytiva’s FlexFactory platform to support integrated, end-to-end production of mRNA-based therapies from laboratory to commercial scale, enhancing in-region manufacturing capabilities for RNA-based therapeutics
• In July 2024, Moderna entered a collaboration with Mitsubishi Tanabe Pharma to promote its mRNA respiratory vaccine portfolio in Japan, expanding commercialization reach in Asia
• In May 2024, GenScript launched a self-amplifying RNA synthesis service for advanced therapeutic applications, boosting potency and efficiency for vaccine, immunotherapy, and gene therapy development
• In June 2023, Samsung Biologics and Pfizer announced a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product portfolio, under which Samsung Biologics provided additional capacity for the large-scale manufacturing of a biosimilar’s portfolio covering oncology, inflammation, and immunology, using its newest facility, Plant 4

Report Scope

Global Vaccines Market Segmentation

This report by Medi-Tech Insights provides the size of the global vaccines market at the regional and country-level from 2024 to 2031. The report further segments the market by vaccine type, route of administration, disease type, age, and distribution channel.

Market Size & Forecast (2024-2031), By Vaccine Type, USD Billion

• Recombinant Vaccines
• Conjugate Vaccines
• Inactivated
• Live Attenuated
• Viral Vector Vaccines
• mRNA Vaccines
• Others

Market Size & Forecast (2024-2031), By Route of Administration, USD Billion

• Oral
• Parenteral
• Nasal

Market Size & Forecast (2024-2031), By Disease Type, USD Billion

• Viral Diseases
• Hepatitis
• Influenza
• HPV
• MMR
• Rotavirus
• Herpes Zoster
• Covid-19
• Others
• Bacterial Vaccines
• Meningococcal Diseases
• Pneumococcal diseases
• DPT
• Others
• Cancer Vaccines
• Allergy Vaccines
• Others

Market Size & Forecast (2024-2031), By Age, USD Billion

• Paediatric
• Adult

Market Size & Forecast (2024-2031), By Distribution Channel, USD Billion

• Hospitals
• Retail Pharmacies
• Government Suppliers
• Others

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa